MDMA‐assisted psychotherapy reduces PTSD symptom severity

A recent study suggests that prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of MDMA-assisted therapy for post-traumatic stress disorder (PTSD). The researchers note that MDMA is close to being approved as the first psychedelic drug for treating PTSD. The finding indicates that a history of SSRI use could limit the therapeutic benefits of MDMA in this context.

Study at a glance

Abstract

Prior use of selective serotonin reuptake inhibitors (SSRIs) may reduce the effectiveness of 3,4‐methylenedioxymethamphetamine (MDMA)‐assisted therapy for post‐traumatic stress disorder (PTSD), say researchers of a recent study who noted that MDMA is close to being considered the first psychedelic drug approved to treat PTSD.